Encore! EP282: Do You Know How Much Cancer Centers Get Paid to Put Patients on Drugs? With Aaron Mitchell, MD, MPH
Relentless Health ValueJune 02, 2022
282
33:2145.79 MB

Encore! EP282: Do You Know How Much Cancer Centers Get Paid to Put Patients on Drugs? With Aaron Mitchell, MD, MPH

After that recent episode with Scott Haas (EP365), where we talked about the real deal with PBM contracting, I kicked into high gear trying to untangle this whole apocalyptic honky-tonk we call benefits for prescription drugs. Notice I did not say prescription drug benefits because that would imply that pharmaceuticals are only charged for under the umbrella of pharmacy benefits. Ha ha, that would be just too easy. No, some pharma drugs are charged as part of patients’ medical benefits. An amazing primer for what that looks like in the real world follows.  

Just pointing out that any self-respecting healthcare market distortion deserves another, and if anything qualifies as a market distortion, it’s buy and bill—what I talk about with Dr. Mitchell in this healthcare podcast. In the following weeks, we’ll chat about how the market has responded to this buy and bill market distortion that we talk about in this episode. So, next week, we’re gonna get into all the different kinds of bagging: the so-called brown bagging, the white bagging, the clear bagging … and what is this newfangled gold bagging? Spoiler alert there. Tune in next week.

And here’s another spoiler alert: While in this show today we chat about how provider organizations tend to make somewhere between 4.5% and 20% additional over drug costs, there was a recent study claiming that 4.5% to 20% is chump change. Some provider organizations are, in fact, making four times to six times the cost of the drug—a very expensive drug, mind you (lots of zeros here)—in profit. In the show in two weeks, I’m speaking with April Yongchu and Erik Davis from USI about exactly and specifically how provider organizations can manage to perform this “let’s make hundreds of thousands of dollars today” magic trick. So, with that, here’s your encore.

In the April [2020] issue of Value-Based Cancer Care (that’s a journal), there’s an article talking about a keynote presentation and a study highlighting a big problem for patients with cancer: toxicity. It’s a fact that some chemo agents are pretty toxic, but in this healthcare podcast I am talking about financial toxicity. The financial burden of cancer care has a seriously negative influence on patients’ quality of life.

This keynote speaker quoted in the Value-Based Cancer Care article implored his fellow oncologists: “Think twice before ordering costly interventions that may have little impact on the clinical course,” he said.

This might be difficult for a number of reasons, and one of them is that oncology centers make money, a whole lot of money, sometimes the most money, from infusing cancer medications. It’s this little payment paradigm called “buy and bill.” The cancer center buys the meds and then gets paid an additional fee to infuse the drug. This fee is a percentage of the drug cost.

You’ve probably heard a lot lately about the skyrocketing costs of some of these cancer agents. Realize that if you’re an oncology center, the higher the drug costs, the higher your revenue. Now consider the patient suffering under the weight of increased cost sharing and employers and taxpayers who are funding this strange payment model.

In this healthcare podcast, I dig into this so-called “buy and bill” payment model with Aaron Mitchell, MD, MPH. Dr. Mitchell is an oncologist and health services researcher over at Memorial Sloan Kettering.

You can learn more at drugpricinglab.org. You can also connect with Dr. Mitchell on Twitter at @TheWonkologist.  

Aaron Mitchell, MD, MPH, is a practicing medical oncologist and health services researcher. He is an assistant attending at Memorial Sloan Kettering Cancer Center in the department of epidemiology and biostatistics. His research focuses on understanding how the financial incentives in the healthcare system affect physician practice patterns and care delivery to cancer patients. He cares for patients with prostate and bladder cancer.

 


04:34 Following the drug and following the dollar.
04:56 The “buy and bill” system.
05:43 The perverse and problematic incentives of the system.
08:38 “It creates the incentive for us to gravitate toward the more expensive drug.”
08:42 The hesitancy to address the financial toxicity of drugs for patients.
09:53 Why the only person losing in this situation is the patient.
10:51 The financial impact from the patient perspective.
13:57 Are patients realizing this impact?
14:42 Solving the problem of oncology drug choice.
16:45 Reimbursement reform.
18:24 Capitated systems and incrementalist impacts to reimbursement reform, and what these look like.
23:30 Are we at a tipping point?
23:51 “The current system … works too well for too many people.”
25:01 Who isn’t well served by the current system.
25:32 Who has to lead the charge for change.
28:28 Large oncology providers vs small oncology providers in the buy and bill system.

 

You can learn more at drugpricinglab.org. You can also connect with Dr. Mitchell on Twitter at @TheWonkologist.

digital health,health care reimbursement,healthcare,healthcare business,pharma,memorial sloan kettering cancer center,wonkologist,

Recent Episodes

EP476: Talking Whistleblowing and the Pharma Rebates Whistleblower Case With an Actual Whistleblower, With Ann Lewandowski
May 15, 2025
476
35:4732.75 MB

EP476: Talking Whistleblowing and the Pharma Rebates Whistleblower Case With an Actual Whistleblower, With Ann Lewandowski

Alright, first off, let me calm down any attorneys right outta the gate here. We will not be talking about—at all—the legal activity that is currently ongoing that my guest today, Ann Lewandowski, is involved with. The suit mostly on our radar today is the one where an EBC (employee benefit consult...

EP475: Is This a Moment or a Movement? With Peter Hayes
May 08, 2025
475
34:2531.51 MB

EP475: Is This a Moment or a Movement? With Peter Hayes

I was talking to Peter Hayes, my guest this week; and I said, “Peter, you post a lot about many, many different topics on LinkedIn and elsewhere. If you had to roll up all of your posts into a few main, I don’t know, change-making vectors or forces of change, roads to Damascus, what would they be? ...

EP474: Private Equity in Healthcare—The Big Data Points You Really Need to Know, All Together in One Episode, With Yashaswini Singh, PhD
May 01, 2025
474
41:2637.93 MB

EP474: Private Equity in Healthcare—The Big Data Points You Really Need to Know, All Together in One Episode, With Yashaswini Singh, PhD

Lots of talk and lots of research these days about private equity in healthcare, so I am so pleased to bring you Yashaswini Singh, PhD, who is one of the authors of a lot of that research. Dr. Yashaswini Singh has been spending the last several years trying to understand the corporate transformatio...

EP473: Keeping Patients out of the ER: How Trusted Relationships in Primary Care Should Work. A Take 2 With Kenny Cole, MD
April 24, 2025
473
34:5331.93 MB

EP473: Keeping Patients out of the ER: How Trusted Relationships in Primary Care Should Work. A Take 2 With Kenny Cole, MD

I’m revisiting, in a take two, this episode with Dr. Kenny Cole because I’m listening to it this time with a new focus. That focus is the theme that keeps coming up over and over and over again on Relentless Health Value these past few months. For a full transcript of this episode, click here . If ...

EP472: The Well-Honed, Three-Prong Hospital Playbook to Maximize Revenue From High-Cost Claimants, With Eric Bricker, MD
April 17, 2025
472
35:1732.3 MB

EP472: The Well-Honed, Three-Prong Hospital Playbook to Maximize Revenue From High-Cost Claimants, With Eric Bricker, MD

For a full transcript of this episode, click here . So, let’s continue themes from prior episodes, most particularly the episode from last week with Christine Hale, MD, MBA ( EP471 ), which was also about high-cost claimants and just the impact that they have on the wallets of self-insured employer...

EP471: High-Cost Claimants in 2025 and Beyond—What Is Really Expensive Not to Know? With Christine Hale, MD, MBA
April 10, 2025
471
34:4131.75 MB

EP471: High-Cost Claimants in 2025 and Beyond—What Is Really Expensive Not to Know? With Christine Hale, MD, MBA

Recently on Relentless Health Value, we’ve been tinkering around with a few recurring themes—recurring through lines—that are just true about American healthcare these days. For a full transcript of this episode, click here . If you enjoy this podcast, be sure to subscribe to the free weekly newsle...

EP470: Continuing the ER and Primary Care Through Line Over to Rural Hospitals and Healthcare, With Nikki King, DHA
April 03, 2025
470
35:1032.2 MB

EP470: Continuing the ER and Primary Care Through Line Over to Rural Hospitals and Healthcare, With Nikki King, DHA

So, the show today, it’s sort of an encore but not really an encore because I recorded this whole new introduction that you are currently listening to. And I also did a few inserts that we popped into the show itself. Inserts from the future, you might say. For a full transcript of this episode, cl...

Listen and Follow

Sponsored by Aventria Health Group
©2025 BD Bridges LLC. All Rights Reserved.